UNSPSC 51392606: Metaraminol hydrochloride

This classification denotes an alpha-adrenergic agonist C9H13NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 90698QK27F, chemically known as benzenemethanol, .alpha.-((1s)-1-aminoethyl)-3-hydroxy-, hydrochloride (1:1), (.alpha.r)-, but more generally known as metaraminol hydrochloride, which bears US NIH Compound Identifier 22265. Most nations, for tariff and trade purposes, schedule metaraminol hydrochloride under HS 29399900 and SITC 54149.

As of Q4 2014, METARAMINOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H]([C@@H](C1CCCC(C1)O)O)N.CL.

UNSPSC 51392606 Metaraminol hydrochloride, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal pharmaceutical scope. The single recent opportunity on file is Seminole County, Florida's IFB60459723LAS, posted June 30, 2026, which solicits naloxone and drug deactivation systems for community health initiatives—a different pharmaceutical product class than metaraminol. A second opportunity, Texas HHS's RFI HHS0017013 (April 3, 2026), addresses pharmacy benefit program structure and direct-to-manufacturer prescription contracting rather than procurement of a specific active pharmaceutical ingredient. The code shows no identifiable pattern of state and local solicitation for metaraminol hydrochloride itself, and the tagged opportunities appear to reflect miscoding or administrative categorization rather than genuine demand under this commodity's scope.

Absent recent activity directly targeting metaraminol hydrochloride at the state or local level, the code presents limited immediate pursuit opportunity. The Seminole County naloxone procurement and the Texas HHS pharmacy program inquiry do not represent a viable pipeline for vendors supplying metaraminol hydrochloride. Business development activity under this code should focus on monitoring state pharmaceutical purchasing vehicles, state health department centralized contracts, and cooperative purchasing organizations for future opportunities—particularly state Medicaid programs and emergency medical services procurement—rather than expecting near-term solicitations grounded in the recent posting history.